Tauriga Sciences Inc. to Resume the Clinical Development of its Proposed “Anti-Nausea” Pharmaceutical Grade Version of Tauri-Gum
The Company expects to issue a material update to shareholders, within the near term (concerning the resumption of this Pharmaceutical Development Work).
- The Company expects to issue a material update to shareholders, within the near term (concerning the resumption of this Pharmaceutical Development Work).
- The delivery system for this proposed Pharmaceutical version is a modified version (substantially higher concentration of CBD) of the existing Tauri-Gum chewing gum formulation based on continued research and development.
- On March 18, 2020 the Company announced that it had filed a Provisional U.S. Patent covering its Pharmaceutical grade version of Tauri-Gum.This patent application, filed with the United States Patent & Trademark Office (U.S.P.T.O.
- Such forward-looking statements are made only as of the date of this release, and Tauriga assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances.